We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Precision Makes dPCR a Steadily Growing Sector

By LabMedica International staff writers
Posted on 06 Apr 2015
Print article
Kalorama Information (New York, NY, USA) has estimated that the budding market for digital PCR (dPCR) reached USD 175 million in 2014 and anticipated growth to provide products for research and diagnostics in diseases like cancer and neurological disorders.

Findings from Kalorama’s dPCR market analysis are provided in its report “qPCR and dPCR Markets,” covering instruments, reagents, software, and services. The report breaks out the market for clinical (in vitro diagnostics) and research applications sectors.

dPCR uses molecular counting to deliver an absolute measure of target nucleic acid molecules, rather than the relative measure obtained from qPCR. It works by partitioning the sample, into chambers (cdPCR) or droplets (ddPCR), to retain only a small number of DNA molecules of interest.

“dPCR is growing in popularity in labs because it is precise,” said Bruce Carlson, publisher of Kalorama Information, “It directly counts the number of individual target molecules in a sample and does not use approximation through standard curves.” Targets are counted as 1, non-targets are counted as 0. Because of its precision, dPCR is capable of analyzing complex mixtures and of performing procedures where only small sample amounts are available.

Kalorama’s report said that among developed nations, the US and Europe represent approximately 70% the dPCR market, which is anticipated to grow at a steady pace, whereas the qPCR segment is mature. “Companies will be looking to provide products to increase research and diagnostics in diseases like cancer, Alzheimer’s disease, and Parkinson’s disease,” said Mr. Carlson.

The competitive landscape for qPCR and dPCR markets is diverse, including large life sciences companies, large pharmaceutical company divisions, and many smaller niche players. According to the report, leading players in this arena are currently Life Technologies (Thermo Fisher Scientific), Bio-Rad, Qiagen, Roche and Agilent, Fluidigm and RainDance Technologies.

Related Links:

Kalorama Information
qPCR and dPCR Markets (Instruments, Reagents, Software/Services, Clinical and Research Markets), report


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.